financetom
Business
financetom
/
Business
/
Insurance broker Aon profit beats estimates on strong demand for risk management
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Insurance broker Aon profit beats estimates on strong demand for risk management
Oct 31, 2025 4:29 AM

(Reuters) -Insurance brokerage firm Aon beat Wall Street estimates for third-quarter profit on Friday, amid robust demand for its risk-management solutions.

WHY IT'S IMPORTANT

Despite mounting concerns over the macroeconomic uncertainty, spending on insurance has remained resilient.

Businesses and individuals are prioritizing risk-management products, fueling revenue for Aon and peers, as they work with several insurers to give clients wider coverage.

Brokers generate revenue through commissions based on premiums, tying their performance closely to the insurance industry numbers.

BY THE NUMBERS

Adjusted profit attributable to Aon's shareholders rose to $660 million, or $3.05 per share, for the quarter ended September 30, up from $594 million, or $2.72 per share, a year earlier.

Analysts on average had expected a profit of $2.91 per share, according to data compiled by LSEG.

Revenue from Aon's commercial risk solutions unit jumped 7% to $1.99 billion.

The company also posted revenue growth in both its health and wealth-solutions units.

MARKET CONTEXT

Aon, whose shares have fallen 8.6% this year, is sharpening its focus on core insurance brokerage operations. Last month, it agreed to sell a majority of NFP's wealth business to private equity firm Madison Dearborn Partners for $2.7 billion.

Peer Marsh McLennan's shares tumbled earlier this month after it reported flat operating margins and slowing growth in its risk and insurance business.

Softening rates, an uneven economy and macro uncertainty are weighing on demand from large clients across the industry, analysts have said.

KEY QUOTE

"We remain confident in achieving our full-year 2025 financial targets and are well-positioned to deliver sustainable growth in 2026 and beyond," said CEO Greg Case in a statement.

(Reporting by Ateev Bhandari in Bengaluru; Editing by Sriraj Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--FTC Sues to Block Edwards Lifesciences' JenaValve Acquisition, Bloomberg Reports
--FTC Sues to Block Edwards Lifesciences' JenaValve Acquisition, Bloomberg Reports
Aug 6, 2025
01:54 PM EDT, 08/06/2025 (MT Newswires) -- Price: 78.00, Change: -1.24, Percent Change: -1.56 ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Hedge fund Cinctive gains 3% in July, source says
Hedge fund Cinctive gains 3% in July, source says
Aug 6, 2025
By Carolina Mandl and Nell Mackenzie NEW YORK, Aug 6 (Reuters) - Hedge fund Cinctive Capital Management gained 3% in July, a performance driven by bets on stocks, a source familiar with the matter said. A multi-strategy hedge fund with various portfolio managers trading different assets and strategies globally, Cinctive outperformed the S&P 500 last month. The index was up...
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve
Aug 6, 2025
(Reuters) -The U.S. Federal Trade Commission sued to block Edwards Lifesciences Corp's acquisition of JenaValve Technology Inc, saying in a lawsuit filed in Washington on Wednesday the merger would decrease competition in the market for a device meant to treat a potentially fatal heart condition. Edwards and JenaValve are the only two companies in the U.S. currently conducting clinical trials...
Copyright 2023-2026 - www.financetom.com All Rights Reserved